TORONTO, Jan. 20 /CNW/ - GeneNews Limited (TSX: GEN), a company focused
on developing blood-based biomarker tests for the early detection of diseases
and personalized health management, today announced that Mr. Colin T. West has
retired from the position of Chief Financial Officer, Vice President of
Finance and Treasurer of GeneNews as of December 31, 2008. The Board of
Directors has appointed Mr. Sonny Young CA to the role of Vice President of
Finance and Treasurer, effective January 1, 2009. Mr. West will remain with
the Company until March 31, 2009, to assist in the transition.
"Colin has been a valued member of the management team for the past two
years. We thank him and wish him well in his retirement," said Dr. Heiner
Dreismann, Lead Director and Interim CEO of GeneNews. "Sonny has been working
with GeneNews since April 2006 as a financial consultant. His breadth of
experience in financial management makes him well-suited to take on the role
of Vice President of Finance and Treasurer."
GeneNews also announced that Mr. Gino Ariano has been appointed to the
newly created role of Senior Director, Sentry Business Unit. Mr. Ariano is
responsible for the sales and marketing of ColonSentry(TM) throughout Canada.
"Gino's broad experience with the marketing and reimbursement of both
medical device and pharmaceutical products will greatly support our efforts to
establish and build our Sentry business in Canada, beginning with our lead
product, ColonSentry" said Gailina Liew, COO of GeneNews. "We are pleased to
welcome Gino to our management team."
Mr. Ariano was at Medtronic Canada for more than 10 years, most recently
as a National Sales Manager and, prior to that, Government Relations and
Reimbursement Manager. Prior to his tenure at Medtronic, he spent nine years
with Glaxo Canada (now GSK) with responsibility for a number of pharmaceutical
Mr.Young is the former Director of Corporate Compliance for OccuLogix.
Prior to his role at OccuLogix, he was the Controller at Sanofi-Synthelabo and
the Director of Financial Accounting at TLC Vision Corp.
GeneNews is focused on the application of functional genomics to enable
early diagnosis and personalized therapeutic intervention based on
disease-specific biomarkers. The Company has developed a novel approach, the
Sentinel Principle(TM), to detect and stage virtually any disease or medical
condition from a simple blood sample. GeneNews is currently applying the
Sentinel Principle(TM) in major areas with unmet clinical needs such as
cancer, arthritis, cardiovascular disease and neurological disorders. For more
information on GeneNews, visit www.genenews.com.
This press release contains forward-looking statements, which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual events could differ
materially from those projected herein. Investors should consult the Company's
ongoing quarterly filings and annual reports for additional information on
risks and uncertainties relating to these forward-looking statements. The
reader is cautioned not to rely on these forward-looking statements. The
Company disclaims any obligation to update these forward-looking statements.
For further information:
For further information: James Smith, (416) 815-0700 x 229,